Efdamrofusp Alfa Biosimilar – Anti-VEGFC fusion protein – Research Grade

Efdamrofusp Alfa Biosimilar – Anti-VEGFC Fusion Protein: A Novel Therapeutic Antibody Targeting Vascular Endothelial Growth Factor C

Introduction

Efdamrofusp Alfa Biosimilar is a novel anti-VEGFC fusion protein that has recently gained attention as a potential therapeutic antibody for various diseases. This biosimilar is a recombinant protein that mimics the structure and function of endogenous Efdamrofusp Alfa, a naturally occurring protein in the human body. In this article, we will discuss the structure, activity, and potential applications of Efdamrofusp Alfa Biosimilar as a therapeutic antibody.

Structure of Efdamrofusp Alfa Biosimilar

Efdamrofusp Alfa Biosimilar is a fusion protein composed of two distinct domains: an anti-VEGFC antibody and a modified form of human Efdamrofusp Alfa. The anti-VEGFC antibody is derived from a monoclonal antibody that specifically binds to vascular endothelial growth factor C (VEGFC), a protein involved in angiogenesis and lymphangiogenesis. The modified Efdamrofusp Alfa domain is a fusion of the human Efdamrofusp Alfa protein and an Fc region of human immunoglobulin G1 (IgG1), which provides stability and prolongs the half-life of the protein in circulation.

The overall structure of Efdamrofusp Alfa Biosimilar is similar to that of other therapeutic antibodies, with a heavy chain and a light chain connected by disulfide bonds. The anti-VEGFC antibody domain is responsible for binding to VEGFC, while the modified Efdamrofusp Alfa domain acts as a carrier and enhances the stability of the protein.

Activity of Efdamrofusp Alfa Biosimilar

Efdamrofusp Alfa Biosimilar is a potent inhibitor of VEGFC, which plays a crucial role in the growth and spread of cancer cells. By binding to VEGFC, this biosimilar prevents its interaction with its receptors, VEGFR-2 and VEGFR-3, on the surface of endothelial and lymphatic cells. This, in turn, inhibits the signaling pathways involved in angiogenesis and lymphangiogenesis, leading to the suppression of tumor growth and metastasis.

In addition to its anti-

cancer activity, Efdamrofusp Alfa Biosimilar also has potential therapeutic applications in other diseases, such as macular degeneration and diabetic retinopathy. These conditions are characterized by abnormal blood vessel growth in the eye, which can lead to vision loss. By targeting VEGFC, this biosimilar can inhibit the formation of new blood vessels and prevent further damage to the retina.

Applications of Efdamrofusp Alfa Biosimilar

Efdamrofusp Alfa Biosimilar is currently being studied as a potential treatment for various types of cancer, including breast, lung, and colorectal cancer. It has shown promising results in preclinical studies, and clinical trials are underway to evaluate its safety and efficacy in cancer patients.

In addition, this biosimilar is also being investigated as a treatment for macular degeneration and diabetic retinopathy. These conditions are leading causes of blindness in the elderly and diabetic populations, respectively. By inhibiting VEGFC, Efdamrofusp Alfa Biosimilar has the potential to prevent the progression of these diseases and improve vision in affected individuals.

Conclusion

Efdamrofusp Alfa Biosimilar is a novel anti-VEGFC fusion protein that has shown promising results as a therapeutic antibody in various diseases. Its unique structure, activity, and potential applications make it a promising candidate for the treatment of cancer, macular degeneration, and

ProteoGenix catalogue number PX-TA2011. For research use only.

Target: Efdamrofusp Alfa Biosimilar – Anti-VEGFC fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet